Standing the test of time: Outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment

Karim J. Halazun, Rachel E. Patzer, Abbas A. Rana, Elizabeth C. Verna, Adam D. Griesemer, Ronald F. Parsons, Benjamin Samstein, James V. Guarrera, Tomoaki Kato, Robert S. Brown, Jean C. Emond – 20 June 2014

Analysis of factors associated with portal vein thrombosis in pediatric living donor liver transplant recipients

Joao Seda Neto, Eduardo A. Fonseca, Flávia H. Feier, Renata Pugliese, Helry L. Candido, Marcel R. Benavides, Gilda Porta, Irene K. Miura, Vera B. Danesi, Teresa Guimaraes, Adriana Porta, Cristian Borges, Andre Godoy, Mario Kondo, Paulo Chapchap – 20 June 2014 – The technique of vascular reconstruction plays a major role in the outcome of living donor liver transplantation (LDLT). An increased use of vascular grafts (VGs) as replacements for sclerotic portal veins has become a standard technique for our group.

Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor–null mice by intestinal‐specific farnesoid X receptor reactivation

Chiara Degirolamo, Salvatore Modica, Michele Vacca, Giuseppe Di Tullio, Annalisa Morgano, Andria D'Orazio, Kristina Kannisto, Paolo Parini, Antonio Moschetta – 20 June 2014 – Farnesoid X receptor (FXR) is the master regulator of bile acid (BA) homeostasis because it controls BA synthesis, influx, efflux, and detoxification in the gut/liver axis. Deregulation of BA homeostasis has been linked to hepatocellular carcinoma (HCC), and spontaneous hepatocarcinogenesis has been observed in FXR‐null mice.

Reduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma

Ze‐yang Ding, Guan‐nan Jin, Wei Wang, Wei‐xun Chen, Yan‐hui Wu, Xi Ai, Lin Chen, Wan‐guang Zhang, Hui‐fang Liang, Arian Laurence, Ming‐zhi Zhang, Pran K. Datta, Bixiang Zhang, Xiao‐ping Chen – 20 June 2014 – Transcriptional intermediary factor 1 gamma (TIF1γ) may play either a potential tumor‐suppressor or ‐promoter role in cancer. Here we report on a critical role of TIF1γ in the progression of hepatocellular carcinoma (HCC). Reduced expression of TIF1γ was detected in HCC, especially in advanced HCC tissues, compared to adjacent noncancerous tissues.

Standing the test of time: Outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment

Karim J. Halazun, Rachel E. Patzer, Abbas A. Rana, Elizabeth C. Verna, Adam D. Griesemer, Ronald F. Parsons, Benjamin Samstein, James V. Guarrera, Tomoaki Kato, Robert S. Brown, Jean C. Emond – 20 June 2014

A cell‐surface β‐hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma

Arihiro Aihara, Chiung‐Kuei Huang, Mark J. Olsen, Qiushi Lin, Waihong Chung, Qi Tang, Xiaoqun Dong, Jack R. Wands – 20 June 2014 – Hepatocellular carcinoma (HCC) has a poor prognosis as a result of widespread intra‐ and extrahepatic metastases. There is an urgent need to understand signaling cascades that promote disease progression. Aspartyl‐(asparaginyl)‐β‐hydroxylase (ASPH) is a cell‐surface enzyme that generates enhanced cell motility, migration, invasion, and metastatic spread in HCC. We hypothesize that inhibition of its enzymatic activity could have antitumor effects.

Subscribe to